@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAefrl9op8HNiX2oaZbXSFh-64dHZqU3QFfvwf77v8ZwU> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAefrl9op8HNiX2oaZbXSFh-64dHZqU3QFfvwf77v8ZwU#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasAgent: sub:_2;
    a go:0003824 .
  
  sub:_2 geneProductOf: hgnc:3059;
    a Protein: .
  
  sub:_3 hasAgent: sub:_4;
    a go:0016301 .
  
  sub:_4 geneProductOf: hgnc:3236;
    a Protein: .
  
  sub:_5 occursIn: species:9606;
    rdf:object sub:_3;
    rdf:predicate belv:directlyIncreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "cat(p(HGNC:HBEGF)) => kin(p(HGNC:EGFR))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_7;
    pav:version "1.4" .
  
  sub:_6 prov:value "More recently, ERBB transactivation has been shown to involve other physiological ligands (FIG. 2). The binding of WNT to its seven-pass membrane receptor Frizzled (FZD) transactivates EGFR. The mechanism seems to be similar to that described for GPCRs, as it is rapid and blocked by metalloproteinase inhibitors; however, the target ligand has not been identified. WNT?FZD-mediated transactivation has been observed in normal mammary cells43 and in breast cancer cells (T. Schlange and N.E.H., unpublished observations). Oestradiol (E2) bindingto plasma-membrane-associated oestrogen receptor (ER) has also been shown to rapidly transactivate ERBBs. According to one report, E2-stimulated activation of MMP2 and MMP9 leads to the release of HB-EGF. Tamoxifen, a selective ER modifier (SERM) was shown to transactivate EGFR and ERBB2, and in ERBB2-overexpressing breast cancer cells this reduced the antiproliferative activity of the SERM";
    prov:wasQuotedFrom pubmed:15864276 .
  
  sub:_7 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:15864276;
    prov:wasDerivedFrom beldoc:, sub:_6 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:34.883+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}